Teva Pharmaceutical Industries Limited (TEVA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $31.77. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of TEVA = $51.42 (+61.9% from the current price, the stock appears undervalued). Analyst consensus target is TEVA = $38 (+20.6% upside).
Valuation: TEVA trades at a trailing Price-to-Earnings (P/E) of 24.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.67.
Financials: revenue is $17.3B, +5%/yr average growth. Net income is $1.4B, growing at +23%/yr. Net profit margin is 8.2% (thin). Gross margin is 51.8% (+5.1 pp trend).
Balance sheet: total debt is $17.4B against $7.9B equity (Debt-to-Equity (D/E) ratio 2.2, leveraged). Current ratio is 1.04 (adequate). Debt-to-assets is 42.7%. Total assets: $40.7B.
Analyst outlook: 22 / 46 analysts rate TEVA as buy (48%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 73/100 (Pass), Growth 83/100 (Pass), Past 25/100 (Fail), Health 17/100 (Fail), Moat 84/100 (Pass), Future 46/100 (Partial), Income 45/100 (Partial).
